Resproly is a respiratory system inhalation therapy and device developer.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Zhuhai
State: Guangdong
Zip:
Country: China
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson&s;s Disease.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2021 | Series B | $0 |
CAS Investment Management CAS Investment Management |
4/2022 | Series B | 2 | - |
Fuho Capital Qianhai Fund of Funds Fuho Capital Qianhai Fund of Funds |
8/2019 | Series A | 3 | $7M |
Huaige Capital Shenzhen Yanghe Biopharmaceutical Industry Investment Zhuhai Gree Financial Investment Management Huaige Capital Shenzhen Yanghe Biopharmaceutical Industry Investment Zhuhai Gree Financial Investment Management |
2/2021 | Series B | 1 | $31M |
CAS Investment Management YuanBio Venture Capital Cowin Capital Qianhai Fund Tianfeng Capital Efung Capital CAS Investment Management |
4/2022 | Series B | 2 | - |
Fuho Capital Qianhai Fund of Funds Fuho Capital Qianhai Fund of Funds |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|